566 related articles for article (PubMed ID: 23525418)
1. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
[TBL] [Abstract][Full Text] [Related]
2. Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
Singer DE; Hellkamp AS; Yuan Z; Lokhnygina Y; Patel MR; Piccini JP; Hankey GJ; Breithardt G; Halperin JL; Becker RC; Hacke W; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2015 Mar; 4(3):e001349. PubMed ID: 25736441
[TBL] [Abstract][Full Text] [Related]
3. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Piccini JP; Hellkamp AS; Lokhnygina Y; Patel MR; Harrell FE; Singer DE; Becker RC; Breithardt G; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2014 Apr; 3(2):e000521. PubMed ID: 24755148
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
6. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Mahaffey KW; Hellkamp AS; Patel MR; Hannan KL; Schwabe K; Nessel CC; Berkowitz SD; Halperin JL; Hankey GJ; Becker RC; Piccini JP; Breithardt G; Hacke W; Singer DE; Califf RM; Fox KA
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):470-8. PubMed ID: 23759472
[TBL] [Abstract][Full Text] [Related]
7. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
[TBL] [Abstract][Full Text] [Related]
8. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287
[TBL] [Abstract][Full Text] [Related]
9. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
12. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.
Marcatto LR; Sacilotto L; Bueno CT; Facin M; Strunz CM; Darrieux FC; Scanavacca MI; Krieger JE; Pereira AC; Santos PC
BMC Cardiovasc Disord; 2016 Nov; 16(1):224. PubMed ID: 27855643
[TBL] [Abstract][Full Text] [Related]
14. Improving Anticoagulation Measurement Novel Warfarin Composite Measure.
Razouki Z; Burgess JF; Ozonoff A; Zhao S; Berlowitz D; Rose AJ
Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):600-7. PubMed ID: 26420820
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale for the WARFA trial: a randomized controlled cross-over trial testing the therapeutic equivalence of branded and generic warfarin in atrial fibrillation patients in Brazil.
Freitas CG; Walsh M; Atallah ÁN
BMC Cardiovasc Disord; 2017 Jun; 17(1):148. PubMed ID: 28592234
[TBL] [Abstract][Full Text] [Related]
16. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
Yamamoto R; Nakae Y; Tanaka F; Johkura K
J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
[TBL] [Abstract][Full Text] [Related]
17. Utility of TTR-INR guided warfarin adjustment protocol to improve time in therapeutic range in patients with atrial fibrillation receiving warfarin.
Kosum P; Siranart N; Nissaipan K; Laohapiboolrattana W; Sowalertrat W; Triamamornwooth K; Arunphan R; Sriyom A; Rungpradubvong V
Sci Rep; 2024 May; 14(1):11647. PubMed ID: 38773162
[TBL] [Abstract][Full Text] [Related]
18. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score.
Apostolakis S; Sullivan RM; Olshansky B; Lip GYH
Chest; 2013 Nov; 144(5):1555-1563. PubMed ID: 23669885
[TBL] [Abstract][Full Text] [Related]
19. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.
Urbonas G; Valius L; Šakalytė G; Petniūnas K; Petniūnienė I
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30650565
[No Abstract] [Full Text] [Related]
20. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation.
Van Den Ham HA; Klungel OH; Leufkens HG; Van Staa TP
J Thromb Haemost; 2013 Jan; 11(1):107-15. PubMed ID: 23088617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]